GlassScriptPhysician profile
Jennifer Pauldurai
NPI 1376031401
$1,395.36
in general payments reported to CMS, 2019-2025
12 companies · $429 in 2025
The $429 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $334 · 2024: $632 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $439.94 | 2024-2025 | |
| Abbvie INC. | $228.05 | 2023-2025 | |
| Ge Healthcare | $206.62 | 2024-2025 | |
| Lilly USA, LLC | $183.93 | 2024 | Kisunla, Amyvid |
| Medtronic, INC. | $108.27 | 2023 | Percept PC Brainsense |
| Lundbeck LLC | $68.38 | 2023-2024 | Vyepti, Rexulti |
| Amneal Pharmaceuticals LLC | $35.84 | 2024 | Rytary |
| Pfizer INC. | $29.54 | 2023 | |
| Harmony Biosciences LLC | $26.29 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $23.82 | 2023 | Lumryz |
| Merz Pharmaceuticals, LLC | $23.43 | 2023 | Xeomin |
| Otsuka America Pharmaceutical, INC. | $21.25 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Pauldurai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.